Paper Details

  1. Home
  2. Paper Details

Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality.

Author: BeckerCorina, FreyReiner, HesseChristiane, MückWolfgang, ReberMichael, UngerSigrun

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Riociguat, a soluble guanylate cyclase (sGC) stimulator, demonstrates complete oral absorption, no clinically relevant food effects, and dose-proportional systemic exposure, supporting its suitability for individualized dose adjustment.
Paper Details　
Original Abstract of the Article :
Riociguat (BAY 63-2521) is the first member of a novel class of compounds, the soluble guanylate cyclase (sGC) stimulators. Riociguat has a dual mode of action: it sensitizes sGC to endogenous nitric oxide (NO) and stimulates sGC independent of NO availability. To characterize the biopharmaceutical ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809663/

データ提供：米国国立医学図書館（NLM）

Riociguat: A New Hope for Pulmonary Arterial Hypertension

Riociguat is a novel drug that stimulates soluble guanylate cyclase (sGC), a key enzyme involved in regulating blood pressure. This study investigates the biopharmaceutical properties of riociguat, including its absolute bioavailability, food interactions, and dose proportionality. The researchers found that riociguat has high absolute bioavailability and is not significantly affected by food intake. They also demonstrated that riociguat's exposure is dose proportional, allowing for individualized dose adjustment in clinical settings.

Unlocking the Potential of Riociguat: A Promising Treatment Option

This study provides valuable insights into the pharmacokinetic properties of riociguat, a promising treatment option for pulmonary arterial hypertension (PAH). The high bioavailability and dose proportionality of riociguat make it a more convenient and predictable therapeutic agent. This finding, like discovering a hidden oasis in the desert of PAH treatment, could improve the lives of patients with this challenging condition.

Navigating the Desert of PAH Treatment: A Personalized Approach

This study emphasizes the importance of individualizing treatment regimens for PAH. The dose proportionality of riociguat allows for personalized dose adjustment, ensuring optimal therapeutic effects and minimizing side effects. This approach, like a camel adapting to the unique challenges of the desert landscape, can help us provide personalized and effective treatment for patients with PAH.

Dr. Camel's Conclusion

This study is a beacon of hope for patients with PAH. The favorable pharmacokinetic properties of riociguat make it a promising therapeutic option, offering the potential for individualized dose adjustment and improved treatment outcomes. This research is a testament to the ongoing efforts to find effective and personalized treatments for complex conditions like PAH.
Date :
  1. Date Completed 2016-04-20
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

27096084

DOI: Digital Object Identifier

PMC4809663

Related Literature

Article Analysis
・Effects of riociguat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.